dronabinol has been researched along with n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ginovart, N; Ibanez, V; Millet, P; Moulin-Sallanon, M; Steimer, T; Tournier, BB | 1 |
Ceccarini, J; Henquet, C; Kuepper, R; Lataster, J; Marcelis, M; van Gerven, JM; van Kroonenburgh, M; Van Laere, K; van Os, J | 1 |
2 other study(ies) available for dronabinol and n-((1-allyl-2-pyrrolidinyl)methyl)-5-(3-fluoropropyl)-2,3-dimethoxybenzamide
Article | Year |
---|---|
Chronic Īā¹-tetrahydrocannabinol exposure induces a sensitization of dopamine Dā/ā receptors in the mesoaccumbens and nigrostriatal systems.
Topics: Amphetamine; Analysis of Variance; Animals; Basal Ganglia; Benzamides; Dopamine Agonists; Dopamine Antagonists; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Dronabinol; Drug Interactions; Fluorodeoxyglucose F18; Gene Expression Regulation; Locomotion; Male; Nucleus Accumbens; Positron-Emission Tomography; Protein Binding; Psychotropic Drugs; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; RNA, Messenger; Tritium; Vitamin K 1 | 2012 |
Delta-9-tetrahydrocannabinol-induced dopamine release as a function of psychosis risk: 18F-fallypride positron emission tomography study.
Topics: Administration, Inhalation; Adult; Benzamides; Caudate Nucleus; Dopamine; Dronabinol; Female; Fluorine Radioisotopes; Humans; Male; Positron-Emission Tomography; Psychotic Disorders; Pyrrolidines; Radiopharmaceuticals; Risk Factors; Substance-Related Disorders | 2013 |